The US Is Cracking Down On Rogue Genetic Engineers
By Kristen V. Brown,
Gizmodo
| 01. 31. 2017
David Ishee’s plan was simple, if not exactly free of complication. From the shed that functions as his laboratory in rural Mississippi, he hoped to use genetic engineering to rid dogs of the types of terrible disorders caused by decades of high-end breeding.
Now, on top of the obvious scientific hurdles, Ishee has a new challenge to contend with: the US Food and Drug Administration (FDA).
Ishee is a biohacker, one among a growing number of do-it-yourself scientists that the US government is having an increasingly difficult time figuring out what to do with.
Since the DIY bio community first developed in the early naughts, it has largely avoided government regulation. But in 2017, cheaper equipment and simpler genetic engineering technologies mean that garage scientists can dream much bigger than simply turning yellow yeast red. We now live in a world where anyone can order custom DNA sequences on the internet to tinker with in their home. And the rules that govern genetic engineering today were not written with the foresight that it would one day be possible for...
Related Articles
By Jacob M. Apel, The Baltimore Sun | 08.16.2024
By Neha Kondaveeti, The Austin Chronicle | 08.16.2024
It’s been a busy couple of months in biopolitics, with developments in the US, UK, China, Japan, and implicitly on Mars. Time for a brief roundup.
• • •
Bioethics needs an update
The National Research Act is now 50 years old. It was signed into law on July 12, 1974, as a direct response to publicity about the 1932 “Tuskegee Study of Untreated Syphilis in the Negro Male.” The Hastings Bioethics Forum celebrated its anniversary with an...
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...